These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 19784877

  • 1. Functional imaging in differentiating bronchial masses: an initial experience with a combination of (18)F-FDG PET-CT scan and (68)Ga DOTA-TOC PET-CT scan.
    Kumar A, Jindal T, Dutta R, Kumar R.
    Ann Nucl Med; 2009 Oct; 23(8):745-51. PubMed ID: 19784877
    [Abstract] [Full Text] [Related]

  • 2. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
    Nilica B, Waitz D, Stevanovic V, Uprimny C, Kendler D, Buxbaum S, Warwitz B, Gerardo L, Henninger B, Virgolini I, Rodrigues M.
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
    Morgat C, Vélayoudom-Céphise FL, Schwartz P, Guyot M, Gaye D, Vimont D, Schulz J, Mazère J, Nunes ML, Smith D, Hindié E, Fernandez P, Tabarin A.
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
    [Abstract] [Full Text] [Related]

  • 4. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.
    Putzer D, Gabriel M, Kendler D, Henninger B, Knoflach M, Kroiss A, Vonguggenberg E, Warwitz B, Virgolini IJ.
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):68-75. PubMed ID: 20168288
    [Abstract] [Full Text] [Related]

  • 5. Functional imaging in neuroendocrine tumors: assessment of molecular heterogeneity using [68Ga]Ga-DOTA-TOC and [18F]FDG PET/CT.
    Nogareda Seoane Z, Mallón Araújo MC, Calatayud Cubes A, Barberán Corral C, Domínguez Novoa Y, Cousillas Castiñeira A, Martínez Lago N, de Matías Leralta JM, Pubul Nuñez V.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2024 Feb; 43(3):500011. PubMed ID: 38643835
    [Abstract] [Full Text] [Related]

  • 6. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
    Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, Uprimny C, Kovacs P, Bale R, Virgolini IJ.
    J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
    [Abstract] [Full Text] [Related]

  • 7. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
    Naswa N, Sharma P, Suman Kc S, Lata S, Kumar R, Malhotra A, Bal C.
    Nucl Med Commun; 2012 Jul; 33(7):766-74. PubMed ID: 22531829
    [Abstract] [Full Text] [Related]

  • 8. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
    Naswa N, Sharma P, Gupta SK, Karunanithi S, Reddy RM, Patnecha M, Lata S, Kumar R, Malhotra A, Bal C.
    Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
    [Abstract] [Full Text] [Related]

  • 9. (68)Ga-DOTA-peptide: A novel molecular biomarker for nasopharyngeal carcinoma.
    Khor LK, Loi HY, Sinha AK, Tong KT, Goh BC, Loh KS, Lu SJ.
    Head Neck; 2016 Apr; 38(4):E76-80. PubMed ID: 26275126
    [Abstract] [Full Text] [Related]

  • 10. A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma.
    Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, Gasser RW, Shulkin BL, Url C, Widmann G, Prommegger R, Sprinzl GM, Fraedrich G, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2013 Dec; 40(12):1800-8. PubMed ID: 24072345
    [Abstract] [Full Text] [Related]

  • 11. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.
    Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, Bomanji JB.
    J Nucl Med; 2009 Dec; 50(12):1927-32. PubMed ID: 19910422
    [Abstract] [Full Text] [Related]

  • 12. Role of 68Ga-DOTATOC PET/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid.
    Venkitaraman B, Karunanithi S, Kumar A, Khilnani GC, Kumar R.
    Eur J Nucl Med Mol Imaging; 2014 May; 41(5):856-64. PubMed ID: 24435773
    [Abstract] [Full Text] [Related]

  • 13. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
    Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, von Guggenberg E, Decristoforo C, Warwitz B, Widmann G, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
    [Abstract] [Full Text] [Related]

  • 14. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
    Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ.
    Cancer; 2008 Jun; 112(11):2447-55. PubMed ID: 18383518
    [Abstract] [Full Text] [Related]

  • 15. Combination of (18)-FDG and (68)Ga-DOTATOC PET-CT to differentiate endobronchial carcinoids and inflammatory myofibroblastic tumors.
    Jindal T, Kumar A, Dutta R, Kumar R.
    J Postgrad Med; 2009 Jun; 55(4):272-4. PubMed ID: 20083875
    [Abstract] [Full Text] [Related]

  • 16. 68Ga-DOTATOC PET/CT in the localization of head and neck paraganglioma compared with 18F-DOPA PET/CT and 123I-MIBG SPECT/CT.
    Kroiss AS, Uprimny C, Shulkin BL, Gruber L, Frech A, Url C, Riechelmann H, Sprinzl GM, Thomé C, Treglia G, Kjaer A, Fraedrich G, Virgolini IJ.
    Nucl Med Biol; 2019 Apr; 71():47-53. PubMed ID: 31152973
    [Abstract] [Full Text] [Related]

  • 17. Multicenter comparison of 18F-FDG and 68Ga-DOTA-peptide PET/CT for pulmonary carcinoid.
    Lococo F, Perotti G, Cardillo G, De Waure C, Filice A, Graziano P, Rossi G, Sgarbi G, Stefanelli A, Giordano A, Granone P, Rindi G, Versari A, Rufini V.
    Clin Nucl Med; 2015 Mar; 40(3):e183-9. PubMed ID: 25608152
    [Abstract] [Full Text] [Related]

  • 18. Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: A review.
    Evangelista L, Ravelli I, Bignotto A, Cecchin D, Zucchetta P.
    Clin Imaging; 2020 Nov; 67():113-116. PubMed ID: 32559681
    [Abstract] [Full Text] [Related]

  • 19. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor.
    Hope TA, Pampaloni MH, Nakakura E, VanBrocklin H, Slater J, Jivan S, Aparici CM, Yee J, Bergsland E.
    Abdom Imaging; 2015 Aug; 40(6):1432-40. PubMed ID: 25820755
    [Abstract] [Full Text] [Related]

  • 20. PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids.
    Lococo F, Cesario A, Paci M, Filice A, Versari A, Rapicetta C, Ricchetti T, Sgarbi G, Alifano M, Cavazza A, Treglia G.
    Tumour Biol; 2014 Sep; 35(9):8369-77. PubMed ID: 24850179
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.